FDA approves Acadia’s Daybue Stix for Rett syndrome
Daybue Stix will become available in limited quantities from the first quarter of 2026.
Drug Development
Sobi buys Arthrosi to expand gout treatment pipeline
China’s NMPA approves Sanofi’s rare haematologic disease treatments
Zealand Pharma and OTR to develop metabolic disease therapeutics
Pfizer plans job cuts in Switzerland to reduce expenses
Boehringer’s Jascayd gains China’s NMPA approval for PPF
Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor
Formycon and Zydus sign exclusive agreement for FYB206 supply
